Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    UID:
    gbv_1778713610
    Format: 1 Online-Ressource (92 p.)
    ISBN: 9783845231037
    Series Statement: Munich Intellectual Property Law Center – MIPLC
    Content: This book discusses the implications of the 2009 EU Commission’s Pharmaceutical Sector Inquiry on originator’s opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do indeed impose potential limitations on an originator’s ability to block or delay generic market entry. On the other hand, the book calls for a differentiated assessment of the rather broad allegations made by the sector inquiry. The book thereby presents and thoroughly analyzes six key issues identified by the EU Commission in the inquiry’s final report: Blocking/defensive patenting, patent thickets, patent-related disputes and litigation, follow-on innovation, authorized generic entries and patent settlement agreements as well as interventions into generic marketing authorization. The analysis aims at reducing legal uncertainty by providing a clearer picture of legal boundaries between legitimate and problematic conduct under Arts. 101 and 102 TFEU. The book also puts the sector inquiry’s findings into a forward-looking perspective by highlighting industry trends with the potential to transform traditional originator and generic business models. The author studied economics and law, has gained substantial expertise about strategy development as a consultant to the pharmaceutical industry and currently leads strategic research management at a large life sciences public research organization in Germany
    Note: English
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    UID:
    b3kat_BV037431911
    Format: 91 S. , graph. Darst.
    Edition: 1. Aufl.
    ISBN: 9783832967079 , 3832967079
    Series Statement: MIPLC studies 11
    Note: Dissertation Universität München 2010
    Additional Edition: Erscheint auch als Online-Ausgabe ISBN 978-3-8452-3103-7
    Language: English
    Subjects: Law
    RVK:
    RVK:
    Keywords: Europäische Union ; Generikum ; Innovation ; Geistiges Eigentum ; Wettbewerbsrecht ; Hochschulschrift
    URL: Volltext  (kostenfrei)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    UID:
    gbv_1657105415
    Format: 1 Online-Ressource (91 Seiten) , Diagramme
    Edition: 1. Auflage
    ISBN: 9783845231037
    Series Statement: MIPLC studies volume 11
    Content: Das Buch wertet die Untersuchung des Arzneimittelsektors der Europäischen Kommission aus. Im Mittelpunkt dieser Untersuchung stehen die Praktiken der Pharmaunternehmen, den Wettbewerb durch Generika und die Entwicklung konkurrierender Originalpräparate zu verhindern bzw. zu erschweren. Die interdisziplinäre Arbeit gibt den Entscheidungsträgern der Pharmaindustrie wertvolle Hinweise welche Auswirkungen die Untersuchung hat
    Note: Gesehen am 16.10.2020 , Dissertation Ludwig-Maximilians-Universität München 2010
    Additional Edition: ISBN 9783832967079
    Additional Edition: Erscheint auch als Druck-Ausgabe Philipp, Marc P. Intellectual property related generic defense strategies in the European pharmaceutical market Baden-Baden : Nomos-Verl.-Ges., 2011 ISBN 3832967079
    Additional Edition: ISBN 9783832967079
    Language: English
    Subjects: Law
    RVK:
    RVK:
    Keywords: Europäische Union ; Generikum ; Innovation ; Geistiges Eigentum ; Wettbewerbsrecht ; Hochschulschrift
    URL: Volltext  (kostenfrei)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    UID:
    gbv_106661573X
    Format: 1 Online-Ressource (91 pages)
    ISBN: 9783832967079 , 3845231033 , 3832967079 , 3845231033 , 9783832967079 , 9783845231037
    Series Statement: MIPLC studies v. 11
    Content: Introduction -- Governance framework of Europe's pharmaceutical sector -- Competitive dynamics in Europe's pharmaceutical market -- Potential future limitations for generic defense -- Implications of business model transformations -- Conclusion & managerial recommendation
    Note: Includes bibliographical references (pages 83-91) , doctoral Universität München 2010
    Additional Edition: ISBN 9783832967079
    Additional Edition: Erscheint auch als Druck-Ausgabe
    Additional Edition: Print version Philipp, Marc P Intellectual property related generic defense strategies in the European pharmaceutical market Baden-Baden : Nomos ; MIPLC/Munich Intellectual Property Law Center, ©2011
    Language: English
    Keywords: Hochschulschrift
    URL: Volltext  (kostenfrei)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    UID:
    edocfu_9958982568502883
    Format: 1 electronic resource (92 p.)
    ISBN: 3-8452-3103-3
    Series Statement: MIPLC studies ; v. 11
    Content: This book discusses the implications of the 2009 EU Commission’s Pharmaceutical Sector Inquiry on originator’s opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do indeed impose potential limitations on an originator’s ability to block or delay generic market entry. On the other hand, the book calls for a differentiated assessment of the rather broad allegations made by the sector inquiry. The book thereby presents and thoroughly analyzes six key issues identified by the EU Commission in the inquiry’s final report: Blocking/defensive patenting, patent thickets, patent-related disputes and litigation, follow-on innovation, authorized generic entries and patent settlement agreements as well as interventions into generic marketing authorization. The analysis aims at reducing legal uncertainty by providing a clearer picture of legal boundaries between legitimate and problematic conduct under Arts. 101 and 102 TFEU. The book also puts the sector inquiry’s findings into a forward-looking perspective by highlighting industry trends with the potential to transform traditional originator and generic business models. The author studied economics and law, has gained substantial expertise about strategy development as a consultant to the pharmaceutical industry and currently leads strategic research management at a large life sciences public research organization in Germany.
    Note: "Munich Intellectual Property Law Center." , Thesis--Universität München, 2010. , Introduction -- Governance framework of Europe's pharmaceutical sector -- Competitive dynamics in Europe's pharmaceutical market -- Potential future limitations for generic defense -- Implications of business model transformations -- Conclusion & managerial recommendation. , English
    Additional Edition: ISBN 3-8329-6707-9
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    UID:
    edoccha_9958982568502883
    Format: 1 electronic resource (92 p.)
    ISBN: 3-8452-3103-3
    Series Statement: MIPLC studies ; v. 11
    Content: This book discusses the implications of the 2009 EU Commission’s Pharmaceutical Sector Inquiry on originator’s opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do indeed impose potential limitations on an originator’s ability to block or delay generic market entry. On the other hand, the book calls for a differentiated assessment of the rather broad allegations made by the sector inquiry. The book thereby presents and thoroughly analyzes six key issues identified by the EU Commission in the inquiry’s final report: Blocking/defensive patenting, patent thickets, patent-related disputes and litigation, follow-on innovation, authorized generic entries and patent settlement agreements as well as interventions into generic marketing authorization. The analysis aims at reducing legal uncertainty by providing a clearer picture of legal boundaries between legitimate and problematic conduct under Arts. 101 and 102 TFEU. The book also puts the sector inquiry’s findings into a forward-looking perspective by highlighting industry trends with the potential to transform traditional originator and generic business models. The author studied economics and law, has gained substantial expertise about strategy development as a consultant to the pharmaceutical industry and currently leads strategic research management at a large life sciences public research organization in Germany.
    Note: "Munich Intellectual Property Law Center." , Thesis--Universität München, 2010. , Introduction -- Governance framework of Europe's pharmaceutical sector -- Competitive dynamics in Europe's pharmaceutical market -- Potential future limitations for generic defense -- Implications of business model transformations -- Conclusion & managerial recommendation. , English
    Additional Edition: ISBN 3-8329-6707-9
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    UID:
    almahu_9949711436402882
    Format: 1 electronic resource (92 p.)
    ISBN: 3-8452-3103-3
    Series Statement: MIPLC studies ; v. 11
    Content: This book discusses the implications of the 2009 EU Commission’s Pharmaceutical Sector Inquiry on originator’s opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do indeed impose potential limitations on an originator’s ability to block or delay generic market entry. On the other hand, the book calls for a differentiated assessment of the rather broad allegations made by the sector inquiry. The book thereby presents and thoroughly analyzes six key issues identified by the EU Commission in the inquiry’s final report: Blocking/defensive patenting, patent thickets, patent-related disputes and litigation, follow-on innovation, authorized generic entries and patent settlement agreements as well as interventions into generic marketing authorization. The analysis aims at reducing legal uncertainty by providing a clearer picture of legal boundaries between legitimate and problematic conduct under Arts. 101 and 102 TFEU. The book also puts the sector inquiry’s findings into a forward-looking perspective by highlighting industry trends with the potential to transform traditional originator and generic business models. The author studied economics and law, has gained substantial expertise about strategy development as a consultant to the pharmaceutical industry and currently leads strategic research management at a large life sciences public research organization in Germany.
    Note: "Munich Intellectual Property Law Center." , Thesis--Universität München, 2010. , Introduction -- Governance framework of Europe's pharmaceutical sector -- Competitive dynamics in Europe's pharmaceutical market -- Potential future limitations for generic defense -- Implications of business model transformations -- Conclusion & managerial recommendation. , English
    Additional Edition: ISBN 3-8329-6707-9
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    UID:
    almahu_9947932573602882
    Format: 1 online resource
    Edition: 1. Auflage 2011
    ISBN: 9783845231037 (Online) , 9783832967079 (Print)
    Content: Das Buch wertet die Untersuchung des Arzneimittelsektors der Europäischen Kommission aus. Im Mittelpunkt dieser Untersuchung stehen die Praktiken der Pharmaunternehmen, den Wettbewerb durch Generika und die Entwicklung konkurrierender Originalpräparate zu verhindern bzw. zu erschweren. Die interdisziplinäre Arbeit gibt den Entscheidungsträgern der Pharmaindustrie wertvolle Hinweise welche Auswirkungen die Untersuchung hat.
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Did you mean 3545231038?
Did you mean 3805251033?
Did you mean 3825235033?
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages